VALIRX PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.35 GBX | +1.52% |
|
-2.90% | -43.22% |
| Apr. 22 | Valirx plc Announces Directorate Changes | CI |
| Mar. 21 | ValiRx inks evaluation deal with Imperial College London for research | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.
Calendar
2024-09-24
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.22% | 5.52M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- VAL Stock
- News ValiRx plc
- ValiRX, StingRay Bio Sign Evaluation Agreement for Oncology Drug Candidates
